CBF (CEBPZ) Rabbit Polyclonal Antibody
CNY 1999.00
CNY 3350.00
货期*
2周
规格
推荐一起购买 (1)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
CNY 300.00
CNY 1430.00
Specifications
| Product Data | |
| Applications | WB |
| Recommend Dilution | WB: 1:500~1:1000 IHC: 1:50~1:200 |
| Reactivity | Human, Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Immunogen | Synthetic peptide, corresponding to the N-terminus of Human C/EBP ζ. |
| Specificity | C/EBP ζ (D24) polyclonal antibody detects endogenous levels of C/EBP ζ protein. |
| Isotype | IgG |
| Formulation | Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
| Concentration | 1mg/ml |
| Conjugation | Unconjugated |
| Storage Condition | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. |
| Predicted Protein Size | ~121 kDa |
| Gene Name | CCAAT/enhancer binding protein zeta |
| Database Link | |
| Background | C/EBP family members include C/EBP α, C/EBP β, C/EBP γ, C/EBP δ, C/EBP ε and C/EBP ζ, all of which are capable of forming homodimers or heterodimers with each other. C/EBP ζ, also known as CBF2, NOC1, CHOP10 (C/EBP homologous protein 10), GADD153 (growth arrest and DNA damage-inducible gene 153) or HSPCBF, is a ubiquitously expressed 1,054 amino acid protein that localizes to the nucleus and regulates transcription. More specifically, C/EBP ζ is believed to play a role regulating the expression of CRP (C-reactive protein). Unlike most C/EBP dimers, C/EBP ζ-containing dimers do not bind the classical C/EBP-binding consensus sequence. Rather, C/EBP ζ-containing dimers must associate with RBP-Jκ (another transcription factor) in order to accomplish binding to the C/EBP site. |
| Synonyms | CBF; CBF2; CCAAT/enhancer binding protein zeta; CCAAT binding factor; CCAAT box binding transcription factor; Cebpz; HSPCBF |
| Note | For research use only, not for use in diagnostic procedure. |
| Reference Data | |
Documents
| Product Manuals |
| FAQs |
| SDS |
Resources
| 抗体相关资料 |
Customer
Reviews
Loading...
